Blvr Valves denied for failing step therapy by Humana?

Humana's specific coverage criteria for blvr valves are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Step Therapy Before Covering BLVR Valves — and How to Appeal

Bronchoscopic lung volume reduction (BLVR) valves are used to treat severe, hyperinflated emphysema when conventional medical management has failed to provide adequate relief. Humana's step-therapy policy requires documentation that the patient has completed defined prior treatment steps — typically optimized inhaled pharmacotherapy and formal pulmonary rehabilitation — before BLVR will be authorized. Denials in this category usually occur because Humana's records do not reflect that the required steps were completed, or because the plan's policy requires a specific sequence that the provider did not document in the prior-authorization request.

Step-therapy denials are among the most successfully appealed denial types, because in many cases the patient has already tried the required treatments — the evidence simply was not submitted with the original request.

## Federal Appeal Framework

ACA §2719 requires non-grandfathered plans to provide internal appeal and access to independent external review. ERISA §503 governs full-and-fair review for self-funded employer plans. You typically have roughly four months from your final internal denial to request external review from an Independent Review Organization. If your respiratory status is deteriorating, request expedited review — a decision is required within 72 hours.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's written step-therapy policy for BLVR. Note each required prior step and its documentation standard. 2. File the Level 1 internal appeal by the deadline on your denial notice. Include all step-completion documentation (see below). 3. If the internal appeal is denied, escalate to Level 2 or directly to IRO external review. 4. In parallel, check whether your state has a step-therapy override law — many states require insurers to waive step requirements when a patient has already tried the mandated therapies or when prior therapies are medically contraindicated. Your physician's letter should address this.

## Documentation to Gather

• Diagnosis confirmation: imaging, pulmonary function tests, and hyperinflation metrics from your chart
• Prior pharmacotherapy history: prescription records, dispensing dates, and chart notes documenting the patient's clinical response (or lack thereof) to each inhaled agent
• Pulmonary rehabilitation records: enrollment dates, session attendance logs, and the final progress or discharge note
• Clinical severity documentation: most recent spirometry, diffusing capacity, and any available exercise-tolerance data
• Prescriber medical-necessity letter attesting that required steps have been completed and explaining why BLVR is the appropriate next intervention

## Criteria-Mapping Structure

Retrieve Humana's published coverage policy for BLVR and list every step-therapy requirement. Then map each to a specific document in your records:

| Humana Step-Therapy Requirement | Documentation Demonstrating Completion | |---|---| | Optimized inhaled bronchodilator therapy | [Prescription fill records + chart note dates and outcomes] | | Inhaled corticosteroid trial (if applicable per policy) | [Prescription records + physician note] | | Completed pulmonary rehabilitation program | [Program enrollment + discharge summary] | | Persistent symptoms despite above | [Most recent visit note documenting ongoing dyspnea/functional limitation] |

Presenting this mapping clearly in the appeal letter removes ambiguity and compels the reviewer to address each point individually, significantly improving reversal odds.